IgAN

Immunology·MeSH: Glomerulonephritis, IGA

16 drugs in development·12 companies·5 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
FILSPARI®	Travere Therapeutics, Inc. (TVTX)
xgeva	AMGEN INC (AMGN)

Phase 3(3)

Drug	Company
atrasentan	CHINOOK THERAPEUTICS, INC. (KDNY)
oms721	OMEROS CORP (OMER)
zigakibart	Novartis AG (NVS)

Phase 2(7)

Drug	Company
ADX-038 Dose Level 1	ARS Pharmaceuticals, Inc. (SPRY)
ADX-038 Dose Level 2	ARS Pharmaceuticals, Inc. (SPRY)
AKB-097	Akebia Therapeutics, Inc. (AKBA)
Atacicept	Vera Therapeutics, Inc. (VERA)
Felzartamab	BIOGEN INC. (BIIB)
zaltenibart	OMEROS CORP (OMER)
zigakibart	Novartis AG (NVS)

Preclinical(1)

Drug	Company
zw209	Zymeworks Inc. (ZYME)

Unknown(2)

Drug	Company
Effin'	Ascend Wellness Holdings, Inc. (AAWH)
NGL-Impact A and NGL-Impact HipH (affinity ligands)	REPLIGEN CORP (RGEN)

Phase 1/Phase 2(1)

Drug	Company
bion-1301	CHINOOK THERAPEUTICS, INC. (KDNY)

BioSniper tracks 16 drugs in development for IgAN across 12 companies.

There are 5 clinical trials targeting IgAN tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.